A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers
Articolo
Data di Pubblicazione:
2016
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Basal like; Chemotherapy; Combination treatment; mtor inhibitor; Taxane; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Everolimus; Female; Furans; Humans; Ketones; Maximum Tolerated Dose; Middle Aged; Research Design; Triple Negative Breast Neoplasms; Oncology; Cancer Research
Elenco autori:
Roviello, Giandomenico; Milani, Manuela; Gobbi, Angela; Cappelletti, Maria Rosa; Zanotti, Laura; Senti, Chiara; Bottini, Alberto; Strina, Carla; Sigala, Sandra; Generali, Daniele
Link alla scheda completa:
Pubblicato in: